logo
logo

Novos Closes $3.15M, Aims To Extend Healthy Human Lifespan With Science-Based Supplements

Oct 01, 2021•almost 4 years ago

Amount Raised

$3.15 Million

Round Type

seed

Description

NOVOS, a leading Longevity supplements brand, announced today on International Longevity Day the close of $3.15 million in pre-seed financing led by Resolute Ventures, with support from Arkitekt Ventures, Longevitytech.fund, Awesome People Ventures and 20 institutional investors and noteworthy entrepreneurs.

Company Information

Company

Novos

About

NOVOS was founded in 2018 and launched in October 2020. NOVOS’ goal is to help people live longer, healthier lives by developing science-based products that slow down the aging process. It is the first company to address the nine hallmarks of aging. NOVOS is headquartered in New York City and employs team members in various regions globally. The company has an advisory board of esteemed longevity scientists and discerns itself by its science-based, data-driven approach. NOVOS products are available for order at www.novoslabs.com. Scientific Board Members & Advisors Prof. Dr. George Church, PhD, Dr. Pamela Maher, PhD, Prof. Dr. João Pedro de Magalhães, Phd, Dr. Oliver Medvedik, PhD, Dr. Avi Rosenbaum, PhD, Prof. Dr. Matt Kaeberlein, PhD